Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)

Belantamab mafodotin (belamaf) demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in DREAMM-2 (NCT03525678). Corneal events, specifically keratopathy (including superficial punctate keratopathy and/or microcyst-like epithelial c...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Cancer J
Main Authors: Lonial, Sagar, Nooka, Ajay K., Thulasi, Praneetha, Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Potter, Heather A., Sborov, Douglas, Zaugg, Brian E., Popat, Rakesh, Degli Esposti, Simona, Byrne, Julie, Opalinska, Joanna, Baron, January, Piontek, Trisha, Gupta, Ira, Dana, Reza, Farooq, Asim V., Colby, Kathryn, Jakubowiak, Andrzej
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2021
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8155129/
https://ncbi.nlm.nih.gov/pubmed/34039952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00494-4
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares